The Hang Seng Index rose by 0.39%, adding 99 points to reach 25,774, while the Hang Seng Tech Index declined by 0.11%. Morning session turnover on the Hong Kong market was HKD 145.2 billion.
TENCENT (00700) advanced 2.72%, following the announcement that its cloud division will formally commercialize the Hy3 preview and DeepSeek-V4-Pro models. BrainAura-B (06681) surged over 34% on progress in China's brain-computer interface technology. Reports indicate a multi-center clinical trial for a fully invasive brain-computer interface system with over a hundred channels has commenced at Beijing Tiantan Hospital, involving 32 initial patients, marking the clinical translation stage for China's self-developed high-throughput invasive brain-computer interface technology.
Health Path (02587) gained over 8% before the midday break, benefiting from national policies to improve drug pricing mechanisms, which are expected to boost its real-world study (RWS) business. Boan Biotech (06955) rose 4.7% after announcing a share buyback plan of up to HKD 200 million and receiving approval for BA5101 in Macau, China. Meitu (01357) increased by 5%, having repurchased approximately HKD 174 million worth of shares this year and recently disclosing its AI productivity application annual recurring revenue (ARR) metric for the first time. Maifushi (02556) climbed over 6% again on plans to introduce strategic partners in the intelligent computing industry to strengthen its computing power foundation. Damai Entertainment (01060) rose over 4%, anticipating an annual net profit increase of over HKD 700 million, driven by the popularity of the film "A Love Letter to Grandma."
Lithium battery concept stocks collectively declined. This follows the announcement of a restart plan for the Australian lithium mine Bald Hill, with market participants focused on downstream acceptance of high prices. Ganfeng Lithium (01772) fell 4.8%, Longpan Technology (02465) dropped 5.68%, and Tianqi Lithium (09696) decreased by 4.33%. Juteng International (03336) resumed trading and plunged over 21% after Lens Technology proposed a voluntary general offer at a discount of approximately 45.68%.
